To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to solidify its position as a leader in the biotechnology sector, with a ...

Jan 22 (Reuters) - Insulin delivery device maker Beta Bionics said on Wednesday it was targeting a valuation of as much as $615.9 million in its initial public offering in the United States ...

Non-transfusion-dependent thalassemia encompasses three clinically distinct forms -- beta-thalassaemia intermedia, hemoglobin E/beta-thalassaemia (mild and moderate forms), and al ...

Ahead of the stable launch in March, Google is rolling out Android 15 QPR2 Beta 3 for Pixel devices. Quarterly Platform Releases deliver more significant changes compared to monthly bug fixes.

The year 2025 marked the introduction of a new generation, at least according to demographers at McCrindle, an Australia-based research firm that claims credit for coining the name of the ...

The official Android 16 release timeline states that Google will release the first three beta builds in January, February, and March. A Googler has revealed the potential release dates for these ...

Despite discontinuing the ex vivo program, the company is planning to leverage on the knowledge about the Sickle Cell Disease and Beta thalassemia, built from ReniCel to accelerate the development ...

The company has just one product on the market, Casgevy, which treats transfusion-dependent beta-thalassemia and sickle cell disease, two rare blood disorders. Casgevy has been on the market for a ...